With pharma transforming more rapidly than ever, seven industry vets chart a road map for meeting a changed industry’s challenges. James Chase led the discussion.
House members voice opposition to CMS reprints stance
Nearly two dozen members of Congress signaled solidarity with 41 medical boards and 33 physician associations in opposing the inclusion of textbooks and reprints in Sunshine Act reporting.
Unmet need has turned pharma toward specialty meds. Yet every success reduces unmet need, raising the bar. In this landscape, how do you ensure that a small-audience drug has a compelling value proposition at launch?
Big pharma marketers who’ve been complaining to Washington for decades about the unregulated nibbling at their market shares won historic relief when the Drug Quality and Security Act was signed into law on Nov. 27.